MAM
TVRD

Meeder Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Meeder Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1
Closed – – 2087
2022
Q3 		$0 Hold
1
– – ﹤0.01% 2408
2022
Q2 		$0 Sell
1
-63
-98% -$22.1K ﹤0.01% 2474
2022
Q1 		$28K Buy
+64
New +$26.3K ﹤0.01% 1159
2021
Q4 		– Hold
0
– – – 2410
2021
Q3 		– Hold
0
– – – 2668
2020
Q2 		– Sell
-18
Closed -$9K – 2530
2020
Q1 		$9K Buy
+18
New +$9.78K ﹤0.01% 1584
2017
Q2 		– Sell
-2
Closed -$1K – 1915
2017
Q1 		$1K Sell
2
-45
-96% -$24K ﹤0.01% 1571
2016
Q4 		$15K Buy
+47
New +$15.1K ﹤0.01% 694

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meeder Asset Management's TVRD Position: Q4 2022 in Review

Meeder Asset Management sold out of Tvardi Therapeutics (TVRD) in Q4 2022, closing a stake of 1 share.

Meeder Asset Management first reported a position in TVRD in Q4 2016 and held it in 6 quarters. The position peaked at $28K in Q1 2022. 159 funds tracked by Wall St. Rank hold TVRD as of Q4 2022.

  • Meeder Asset Management reported no remaining Tvardi Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Meeder Asset Management sold 1 Tvardi Therapeutics share in Q4 2022.
  • Meeder Asset Management first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 6 quarters.
  • Meeder Asset Management's Tvardi Therapeutics position peaked at $28K in Q1 2022.
  • 159 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.